Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016809
Chunk: 102

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 102
---
 costs, in criminal cases where the director is convicted, or in civil cases brought by the company where the
final judgment goes against the director.

The Registrant has entered into a deed
of indemnity with each of its directors and officers. Except as prohibited by applicable law, these deeds of indemnity may require the
Registrant, among other things, to indemnify its directors and officers for certain expenses, including attorneys’ fees, judgments,
fines and settlement amounts incurred by such directors and officers in any action or proceeding arising out of their service as a director
or officer of the Registrant, or one of its subsidiaries, or arising out of the services provided to another company or enterprise at
the Registrant’s request.

Insofar as indemnification for liabilities
arising under the Securities Act of 1933, as amended, may be permitted to directors, officers or persons controlling us pursuant to the
foregoing provisions, we have been informed that in the opinion of the Securities and Exchange Commission such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable.

| Item 7. | Recent Sales of Unregistered Securities |

The following information is furnished
with regard to all securities issued by the Registrant within the last three years that were not registered under the Securities Act of
1933, as amended. Unless otherwise indicated below, the issuance of such shares was deemed exempt from registration requirements of the
Securities Act, of 1933, as amended, as such securities were offered and sold outside of the United States to persons who were neither
citizens nor residents of the United States, pursuant to Regulation S, or such sales were exempt from registration under Section 4(2)
of Securities Act of 1933, as amended and Rule 506 of Regulation D promulgated thereunder.

On February 15, 2023, we completed
the closing of a private placement pursuant to which we sold to certain institutional investors (1) 3,250,000 Ordinary Shares represented
by 32 Depositary Shares at $46,400.00 per Depositary Share, (2) 12,931,020 Ordinary Shares represented by 129 Depositary Shares, issuable upon the exercise of Series A Warrants issued in the private placement at an exercise price of $53,600.00 per warrant, (3) 19,396,400 Ordinary Shares represented by 193 Depositary Shares, issuable upon the exercise of Series B Warrants